[go: up one dir, main page]

FR2873925B1 - Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes - Google Patents

Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Info

Publication number
FR2873925B1
FR2873925B1 FR0408667A FR0408667A FR2873925B1 FR 2873925 B1 FR2873925 B1 FR 2873925B1 FR 0408667 A FR0408667 A FR 0408667A FR 0408667 A FR0408667 A FR 0408667A FR 2873925 B1 FR2873925 B1 FR 2873925B1
Authority
FR
France
Prior art keywords
erythrocytes
lysis
suspension
rescaling
lyse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0408667A
Other languages
English (en)
Other versions
FR2873925A1 (fr
Inventor
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34949346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2873925(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to FR0408667A priority Critical patent/FR2873925B1/fr
Priority to PL05768180T priority patent/PL1773452T3/pl
Priority to AT05768180T priority patent/ATE532504T1/de
Priority to CA2892729A priority patent/CA2892729C/fr
Priority to CN2005800298147A priority patent/CN101031339B/zh
Priority to CA2575617A priority patent/CA2575617C/fr
Priority to DK05768180.1T priority patent/DK1773452T3/da
Priority to AU2005270977A priority patent/AU2005270977B2/en
Priority to SI200531459T priority patent/SI1773452T1/sl
Priority to PT05768180T priority patent/PT1773452E/pt
Priority to US11/573,093 priority patent/US8617840B2/en
Priority to PCT/IB2005/002323 priority patent/WO2006016247A2/fr
Priority to EP10183315.0A priority patent/EP2277594B1/fr
Priority to JP2007524421A priority patent/JP4598827B2/ja
Priority to ES05768180T priority patent/ES2376979T3/es
Priority to HK08101485.2A priority patent/HK1110030B/xx
Priority to EP05768180A priority patent/EP1773452B1/fr
Priority to KR1020077004994A priority patent/KR101332733B1/ko
Publication of FR2873925A1 publication Critical patent/FR2873925A1/fr
Publication of FR2873925B1 publication Critical patent/FR2873925B1/fr
Application granted granted Critical
Priority to US14/089,834 priority patent/US10273444B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Sustainable Development (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0408667A 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes Expired - Lifetime FR2873925B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR0408667A FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US11/573,093 US8617840B2 (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes
EP10183315.0A EP2277594B1 (fr) 2004-08-05 2005-08-04 Procédé et dispositif de lyse-rescellement pour l'incorporation de principe actif dans des érythrocytes
CA2892729A CA2892729C (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
CN2005800298147A CN101031339B (zh) 2004-08-05 2005-08-04 将活性成份掺入红细胞的裂解/再封方法和装置
CA2575617A CA2575617C (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
DK05768180.1T DK1773452T3 (da) 2004-08-05 2005-08-04 Fremgangsmåde til lysis/genlukning med henblik på inkorporering af et aktivt stof i erythrocytter
AU2005270977A AU2005270977B2 (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
SI200531459T SI1773452T1 (sl) 2004-08-05 2005-08-04 Postopek lizis resealing uvajanja učinkovine v eritrocite
PT05768180T PT1773452E (pt) 2004-08-05 2005-08-04 Processo de lise/resselagem e dispositivo para incorporar um ingrediente activo em eritrócitos
PL05768180T PL1773452T3 (pl) 2004-08-05 2005-08-04 Proces lizy/ponownego zamykania do wprowadzania substancji czynnej do erytrocytów
PCT/IB2005/002323 WO2006016247A2 (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
AT05768180T ATE532504T1 (de) 2004-08-05 2005-08-04 Lyse / wiederverschlussverfahren zum einbau eines wirkstoffs in erythrozyten
JP2007524421A JP4598827B2 (ja) 2004-08-05 2005-08-04 活性成分、特にアスパラギナーゼまたはイノシトールヘキサホスフェートを赤血球中に組み込むための溶解／再シーリング方法及び装置
ES05768180T ES2376979T3 (es) 2004-08-05 2005-08-04 Procedimiento de lisis/resellado para incorporar un ingrediente activo en eritrocitos
HK08101485.2A HK1110030B (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
EP05768180A EP1773452B1 (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement permettant d'incorporer un ingredient actif dans des globules rouges
KR1020077004994A KR101332733B1 (ko) 2004-08-05 2005-08-04 적혈구에 활성 성분을 내재화시키는 용해/재봉합 방법 및 장치
US14/089,834 US10273444B2 (en) 2004-08-05 2013-11-26 Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408667A FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Publications (2)

Publication Number Publication Date
FR2873925A1 FR2873925A1 (fr) 2006-02-10
FR2873925B1 true FR2873925B1 (fr) 2006-10-13

Family

ID=34949346

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408667A Expired - Lifetime FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Country Status (15)

Country Link
US (2) US8617840B2 (fr)
EP (2) EP2277594B1 (fr)
JP (1) JP4598827B2 (fr)
KR (1) KR101332733B1 (fr)
CN (1) CN101031339B (fr)
AT (1) ATE532504T1 (fr)
AU (1) AU2005270977B2 (fr)
CA (2) CA2892729C (fr)
DK (1) DK1773452T3 (fr)
ES (1) ES2376979T3 (fr)
FR (1) FR2873925B1 (fr)
PL (1) PL1773452T3 (fr)
PT (1) PT1773452E (fr)
SI (1) SI1773452T1 (fr)
WO (1) WO2006016247A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
FR2891843A1 (fr) * 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
CN101583722A (zh) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
KR100828018B1 (ko) * 2006-11-20 2008-05-08 레인보우스케이프주식회사 수질정화용 여과재
AP2937A (en) * 2007-04-20 2014-07-31 Gen Hospital Corp Method for counting cells
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
US20100316620A1 (en) * 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
FR2938332B1 (fr) * 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
FR2940087B1 (fr) * 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
EP2199791B1 (fr) * 2008-12-19 2019-05-01 F. Hoffmann-La Roche AG Méthode pour evaluer l'hémolyse dans les érythrocytes et dispositif associé
FR2944106B1 (fr) * 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
PT2493487T (pt) * 2009-10-27 2016-11-08 Erytech Pharma Composição para induzir uma tolerância imunitária específica
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
WO2013019290A2 (fr) * 2011-04-21 2013-02-07 Streck, Inc. Témoin de référence pour fraction de réticulocytes immatures et procédé apparentés
WO2013139906A1 (fr) 2012-03-21 2013-09-26 Erytech Pharma Médicament pour le traitement de la leucémie myéloïde aiguë (aml)
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
SG11201509252QA (en) * 2013-05-10 2015-12-30 Erydel Spa Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
EP2813234A1 (fr) 2013-06-11 2014-12-17 Erytech Pharma Composition d'érythrocytes encapsulant phenylalanine hydroxylase et l'emploi thérapeutique
KR102386122B1 (ko) 2013-08-16 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
WO2015073587A2 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthétique- récepteur
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
PL3125927T3 (pl) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Sposoby i kompozycje do immunomodulacji
KR102819064B1 (ko) 2014-10-31 2025-06-12 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
WO2016115179A1 (fr) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Édition de gène par administration microfluidique
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
EP3344575B1 (fr) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire
WO2017084683A1 (fr) * 2015-11-20 2017-05-26 Hepa Wash Gmbh Procédé pour assistance pulmonaire extracorporelle
EP3187190A1 (fr) 2015-12-31 2017-07-05 Erytech Pharma Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine
AU2017207738A1 (en) 2016-01-11 2018-07-12 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cancer indications
IL262677B2 (en) * 2016-05-03 2025-08-01 Sqz Biotechnologies Co Intracellular delivery of biomolecules to suppress an immune response or to induce tolerance to an antigen in an individual
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3449935A1 (fr) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulée à l'intérieur des érythrocytes et leur utilisation dans le traitement du cancer et de la déficience en arginase-1
WO2019042628A1 (fr) 2017-08-31 2019-03-07 Erytech Pharma Arginine déiminase encapsulée à l'intérieur d'érythrocytes et leur utilisation dans le traitement du cancer et d'une déficience en arginase-1
WO2019113157A1 (fr) 2017-12-05 2019-06-13 Aerase, Inc. Procédé et composition pour le traitement d'une déficience en arginase 1
IL278538B2 (en) 2018-05-09 2024-01-01 Univ Chicago Compositions and methods concerning immune tolerance
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
AU2019362059B2 (en) 2018-10-19 2025-11-27 Immedica Pharma Ab Arginine depletion therapy for treatment of GAMT deficiency
US20210403571A1 (en) 2018-11-15 2021-12-30 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
CN113660899B (zh) * 2019-04-01 2024-05-14 吉温成象有限公司 体内免疫测定系统
WO2021041904A1 (fr) 2019-08-30 2021-03-04 Aeglea Biotherapeutics, Inc. Procédés de production d'arginase 1 de recombinaison humaine et utilisations associées
CA3178252A1 (fr) 2020-05-11 2021-11-18 Erytech Pharma Vesicules extracellulaires de globules rouges (vecgr) contenant des cargos et procedes d'utilisation et de production de celles-ci
US20220313798A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
WO2023027613A1 (fr) * 2021-08-27 2023-03-02 Общество С Ограниченной Ответственностью "Рбк-Фармэко" Dispositif et procédé pour inclure des composants bio-actifs dans des érythrocytes selon un procédé de dialyse continue
WO2023067200A1 (fr) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulée dans des globules rouges pour le traitement du cancer du pancréas
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5468291A (en) * 1977-11-10 1979-06-01 Mitsubishi Chem Ind Method of measuring osmotic pressure resistance of corpuscle membrane
US4327710A (en) * 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) * 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
US4801777A (en) * 1987-09-03 1989-01-31 Vanderbilt University Blood rewarming method and apparatus
FR2678512B1 (fr) * 1991-07-03 1995-06-30 Novacell Machine a internaliser.
WO1994021117A1 (fr) * 1993-03-23 1994-09-29 Cbr Laboratories, Inc. Methode et appareil d'encapsulation de substances biologiquement actives dans des cellules
DE69732225T2 (de) * 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
WO2002010177A1 (fr) 2000-08-01 2002-02-07 Gmp Companies, Inc. Sels ammonium d'inositol hexaphosphate et leurs utilisations

Also Published As

Publication number Publication date
US10273444B2 (en) 2019-04-30
EP2277594B1 (fr) 2016-03-30
US8617840B2 (en) 2013-12-31
EP2277594A3 (fr) 2011-05-18
CN101031339B (zh) 2012-07-18
CA2892729A1 (fr) 2006-02-16
PT1773452E (pt) 2012-02-08
CA2575617A1 (fr) 2006-02-16
ES2376979T3 (es) 2012-03-21
PL1773452T3 (pl) 2012-04-30
FR2873925A1 (fr) 2006-02-10
EP2277594A2 (fr) 2011-01-26
CA2892729C (fr) 2017-05-09
KR101332733B1 (ko) 2013-11-25
KR20070058478A (ko) 2007-06-08
AU2005270977B2 (en) 2011-11-24
CN101031339A (zh) 2007-09-05
ATE532504T1 (de) 2011-11-15
WO2006016247A2 (fr) 2006-02-16
JP2008508920A (ja) 2008-03-27
DK1773452T3 (da) 2012-02-27
US20140154797A1 (en) 2014-06-05
JP4598827B2 (ja) 2010-12-15
EP1773452A2 (fr) 2007-04-18
HK1110030A1 (en) 2008-07-04
US20080261262A1 (en) 2008-10-23
WO2006016247A3 (fr) 2006-06-22
AU2005270977A1 (en) 2006-02-16
CA2575617C (fr) 2015-10-06
SI1773452T1 (sl) 2012-03-30
EP1773452B1 (fr) 2011-11-09

Similar Documents

Publication Publication Date Title
FR2873925B1 (fr) Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
Kundu et al. Effect of amino acids on goat cauda epididymal sperm cryopreservation using a chemically defined model system
US20240374522A1 (en) Formulations And Methods For Contemporaneous Stabilization Of Active Proteins During Spray Drying And Storage
Reddoch et al. Hemostatic function of apheresis platelets stored at 4 C and 22 C
JP5138372B2 (ja) 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法
Swami et al. Cysteamine supplementation revealed detrimental effect on cryosurvival of buffalo sperm based on computer-assisted semen analysis and oxidative parameters
Radwanski et al. The effects of red blood cell preparation method on in vitro markers of red blood cell aging and inflammatory response
US20080274092A1 (en) Erythrocytes Containing Arginine Deiminase
Noulsri et al. Effects of donor age, donor sex, blood-component processing, and storage on cell-derived microparticle concentrations in routine blood-component preparation
Rajashekaraiah et al. Platelet storage: progress so far
EP2903432A1 (fr) Procédés de traitement de sperme pour un tri par sexe
CN103702556A (zh) 使用唾液酸酶抑制剂改进的血小板保存
Deyhim et al. L-carnitine effectively improves the metabolism and quality of platelet concentrates during storage
Makley et al. Murine blood banking: characterization and comparisons to human blood
US11589575B2 (en) Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood
US20160081328A1 (en) Solutions for Red Blood Cells
EP1244353A1 (fr) Compositions pour le stockage de plaquettes
US20180208894A1 (en) Sperm processing method, apparatus and related media compositions
Yamashiro et al. Lactate and adenosine triphosphate in the extender enhance the cryosurvival of rat epididymal sperm
Anel‐López et al. The effect of oxidative stress on thawed bulk‐sorted red deer sperm
Zubov et al. Trolox antioxidant as a factor in stabilization of human cord blood nucleated cells during cryopreservation
WO2011089391A1 (fr) Procédés de conservation de cellules de mammifère
CN108018260A (zh) 用于多种细胞因子诱导的杀伤细胞的冷冻复苏液及其应用
Baghdadi et al. The surface markers and survival rate of platelets during storage at 4 C: The influence of sodium octanoate
Fu et al. Effect of DMSO combined with trehalose on cryopreservation of goose semen

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
CA Change of address
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20